Innovative research and application of the clinical scheme of

Guang'anmen Hospital, China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1) After percutaneous coronary stent implantation and conventional Western medical treatment;
•2) TCM syndrome differentiation is the mutual syndrome of stasis, poison and stagnation;
•3) 18-75 years old, gender is not limited;
•4) Heart function classification <= NYHA II Grade and echocardiographic ejection fraction 45%;
•5) Subjects must give informed consent to this trial and sign an informed consent form before the trial.

•1) Stroke (cerebral hemorrhage, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism and stroke of unknown type) within the past 6 months;
•2) Poorly controlled hypertension (>=180/100mmHg) or hypotension (<90/60mmHg);
•3) Combined malignant arrhythmia (ventricular tachycardia, rapid atrial fibrillation, atrial flutter, atrioventricular block above II degree II, complete bundle branch block) recently repeated to the author;
•4) Complicated with severe liver and kidney dysfunction (creatinine clearance <= 40ml/min, serum transaminase >= 2 x upper limit of clinical reference value), other serious primary diseases, tumors or mental diseases that affect life span;
•5) Pregnancy, planned pregnancy or lactation Women;
•6) Known bleeding tendency or bleeding disease, or uncontrollable coagulation mechanism disorder, or active bleeding and invasive examination and treatment operations within 2 weeks, or history of severe trauma or major surgery within 12 weeks;
•7) Those who are participating in other clinical trials;
•8) Those who are allergic to the experimental drugs and their constituents;
•9) The current or past history of drug abuse or drug use;
•10) Suffering from dementia or severe mental disorders that make it unable to understand or express knowledge Those who agree;
•11) Those who are drug or alcohol dependent, or other situations where the researcher thinks it is inappropriate to participate in this study.

发起方